HR-Positive, HER2-Negative Metastatic Breast Cancer Guidelines Pocket Guide - Guideline Central

HR-Positive, HER2-Negative Metastatic Breast Cancer

American Society of Clinical OncologyPublished: May 3, 2024

A PDF version of this Pocket Guide is also available!
$9.95
A digital version of this pocket guide is available for FREE at this link
  • Introduction
  • Treatment
    • Recommendations from 2024 Rapid Recommendation Update
    • Recommendations from 2023 Rapid Recommendation Update
    • Recommendations from 2021 Focused Guideline Update
    • Recommendations Unchanged from 2016 Guideline
  • Tables
    • Treatment Options According to Prior Endocrine Therapy
    • At-A-Glance Guide to ASCO Biomarker Testing in Metastatic Breast Cancer Recommendations
  • Algorithm
    • Algorithm for Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer


You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.